CXCL8 and glioblastoma: In GBM, several factors promote blood vessel co-option, including bradykinin, breast-derived growth inhibitor, the CXC motif chemokine receptor 4 (CXCR4), EGFRvIII, Angiopoietin-2, IL8, the endoplasmic reticulum to nucleus signaling protein 1 (IRE-1α), and Wnt7 [169].